Chronic Kidney Disease

The AJMC® Chronic Kidney Disease compendium is a comprehensive resource for clinical news and expert insights on the condition and treatment of loss of kidney function.

Latest News

Image Credit: Dusan Petkovic - stock.adobe.com
Drinking Water Contaminants Linked to Higher Chronic Kidney Disease Risk

July 11th 2025

Long-term exposure to water contaminants, even below the regulatory limits, significantly increases the risk of chronic kidney disease.

Medical personnel filing a syringe needle | Image Credit: MargJohnsonVA - stock.adobe.com.jpeg
SGLT2 Inhibitor Offers Kidney Protection and Reduces Heart Failure Risk After Acute Myocardial Infarction

July 10th 2025

FDA Approved. | Image Credit: Nirusmee - stock.adobe.com .jpeg
Oxylanthanum Carbonate Fails to Secure FDA Approval for Hyperphosphatemia, CKD

June 30th 2025

Woman laying on bed with mobile phone, using medical app | Prostock-studio - stock.adobe.com
Smartphone-Powered CKD Screening Yields 2.5-Fold Increase in Testing, Early Diagnoses

June 27th 2025

Clinical trial researchers interact with data | Image Credit: elenabsl - stock.adobe.com .jpeg
Lorundrostat Yields Promising Results for Treatment of Hypertension in Patients with CKD and Albuminuria

June 20th 2025

More News

New Renal, HF Results Seen in 2020 ACC Pathway on CV Risk Reduction
August 5th 2020

New Renal, HF Results Seen in 2020 ACC Pathway on CV Risk Reduction

Mary Caffrey
The American College of Cardiology updates guidance on prescribing SGLT2 inhibitors and GLP-1 receptor agonists to patients with type 2 diabetes and cardiovascular disease or CV risk.
Future Management of Anemia in CKD
August 4th 2020

Future Management of Anemia in CKD

Future Treatment of Anemia in CKD: Impact of HIF Stabilizers
August 4th 2020

Future Treatment of Anemia in CKD: Impact of HIF Stabilizers

Anemia in CKD: HIF Stabilizers in Clinical Trials
August 4th 2020

Anemia in CKD: HIF Stabilizers in Clinical Trials

Payer Perspective of HIF Stabilizers for Anemia in CKD
August 4th 2020

Payer Perspective of HIF Stabilizers for Anemia in CKD

HIF Stabilizers: Management of Anemia in CKD
August 4th 2020

HIF Stabilizers: Management of Anemia in CKD

HIMALAYAS Trial: Long-Term Cardiovascular Safety Data
August 4th 2020

HIMALAYAS Trial: Long-Term Cardiovascular Safety Data

HIF Stabilizers for Anemia in CKD: Phase 3 Trials
August 4th 2020

HIF Stabilizers for Anemia in CKD: Phase 3 Trials

Treatment of Anemia in CKD During COVID-19
August 4th 2020

Treatment of Anemia in CKD During COVID-19

Economic Burden of Anemia in CKD
August 4th 2020

Economic Burden of Anemia in CKD

Anemia in CKD: CHOIR and TREAT Trials
August 4th 2020

Anemia in CKD: CHOIR and TREAT Trials

Standard of Care: Therapeutic Options for Anemia in CKD
August 4th 2020

Standard of Care: Therapeutic Options for Anemia in CKD

Treatment of Anemia in CKD
August 4th 2020

Treatment of Anemia in CKD

Payer Perspective of Anemia in CKD
August 4th 2020

Payer Perspective of Anemia in CKD

Role of Anemia in CKD
August 4th 2020

Role of Anemia in CKD

Overview of Chronic Kidney Disease
August 4th 2020

Overview of Chronic Kidney Disease

FDA Grants Orphan Drug Status to Regulus Therapeutics' Treatment for Common Type of PKD
July 30th 2020

FDA Grants Orphan Drug Status to Regulus Therapeutics' Treatment for Common Type of PKD

Mary Caffrey
Although the name suggests the disease affects only the kidneys, development of fluid-filled cysts can spread to the liver, the pancreas, and other organs. While a healthy kidney is about the size of a fist, a kidney filled with cysts from polycystic kidney disease (PKD) can grow to be about the size of a football weigh up to 30 pounds
Dapagliflozin Meets All Targets in Patients With Chronic Kidney Disease, With and Without Diabetes
July 28th 2020

Dapagliflozin Meets All Targets in Patients With Chronic Kidney Disease, With and Without Diabetes

Mary Caffrey
Data from DAPA-CKD show that the trial met all its primary and secondary end points for patients with chronic kidney disease, with and without type 2 diabetes. The announcement comes after a data monitoring committee halted the trial in March 2020 when it found the evidence of efficacy was overwhelming.
When Should Renal Replacement Therapy Start After Acute Kidney Injury?
July 25th 2020

When Should Renal Replacement Therapy Start After Acute Kidney Injury?

Mary Caffrey
Just when renal replacement therapy should start after acute kidney injury has been debated.
National Kidney Foundation, NCQA Announce Measure to Boost Testing in Patients With Diabetes
July 24th 2020

National Kidney Foundation, NCQA Announce Measure to Boost Testing in Patients With Diabetes

AJMC Staff
While clinical guidelines call for those with diabetes to be tested regularly for kidney disease, less than 50% of these patients are tested once a year, according to the National Kidney Foundation.
Site Logo
July 16th 2020

Racial, Socioeconomic Disparities Continue in Prevalence of CKD Over Time

Allison Inserro
The authors said the results show a need to develop more targeted interventions for populations at risk of chronic kidney disease (CKD).
Site Logo
July 15th 2020

Profiles of COVID-19 Patients: A Study of Private Health Care Claims

Robin Gelburd, JD
Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects
July 10th 2020

Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects

Mary Caffrey
The coronavirus disease 2019 pandemic presents a new challenge: patients have severe flu-like symptoms, but the virus can also cause renal failure. Doctors and patients need analgesics that go easy on the liver and kidneys but are not addictive, and this week researchers at LSU Health New Orleans Neuroscience Center of Excellence announced they have discovered a new class of drugs that can do the job.
This Week in Managed Care: July 10, 2020
July 10th 2020

This Week in Managed Care: July 10, 2020

This week, the top managed care news included CMS planning to pay more for at-home dialysis equipment; ACR supports continued use of telemedicine after the COVID-19 pandemic passes; AJMC®’s coverage of AIDS 2020, the 23rd International AIDS Conference.
CMS Seeks Incentives for At-Home Dialysis in Wake of COVID-19
July 7th 2020

CMS Seeks Incentives for At-Home Dialysis in Wake of COVID-19

Mary Caffrey
End-stage renal disease has long been one of the most expensive and debilitating conditions that affects Medicare beneficiaries. Not only does dialysis cost $90,000 a year—those awaiting a kidney transplant automatically qualify for Medicare—but the need to travel to a dialysis center multiple times a week disrupts employment and home life.
Frequently Prescribed Allopurinol No Better Than Placebo for CKD in Head-to-Head Trial
July 4th 2020

Frequently Prescribed Allopurinol No Better Than Placebo for CKD in Head-to-Head Trial

Mary Caffrey
Results from the University of New South Wales appeared in the New England Journal of Medicine. The co-lead investigator said the results show the need for more treatment options in chronic kidney disease.
Study of Fat Cells May Hint at Target in Chronic Renal Failure
July 1st 2020

Study of Fat Cells May Hint at Target in Chronic Renal Failure

AJMC Staff
Previously, fat cells, called adipocytes, were not known to have a role in renal failure-associated cardiomyopathy.
Dana-Farber Scientists Find Biomarker for Kidney Cancer
June 25th 2020

Dana-Farber Scientists Find Biomarker for Kidney Cancer

Mary Caffrey
A coauthor of the study said that if the noninvasive test was used more widely, before kidney cancers have spread, fewer people would die from the disease.
Kidney Failure Due to Acute Injury Deadlier Than Diabetes, Data Show
June 23rd 2020

Kidney Failure Due to Acute Injury Deadlier Than Diabetes, Data Show

Mary Caffrey
Acute kidney injury is a sudden onset of kidney damage that causes waste products to build up in the body. These episodes have become more common during the coronavirus disease 2019 pandemic, causing kidney failure in some previously healthy patients who had no prior history of renal problems.
Differences in Basal Insulins for Patients in Renal Failure
June 20th 2020

Differences in Basal Insulins for Patients in Renal Failure

Mary Caffrey
In a poster titled “Basal Insulins in Advanced Renal Failure: Time for a Paradigm Shift,” authors compared the safety and efficacy of insulin degludec (Tresiba) with insulin glargine 100U (Lantus) among patients with stage 3 and stage 4 chronic kidney disease (CKD).
<1
...
678910111213>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo